Waverley Care is delighted that the HIV prevention medication Cabotegravir (Apretude) has been approved today for use within NHS Scotland.
Grant Sugden, Chief Executive of Waverley Care, explains: “The extended-release injection will provide a much-needed alternative for individuals who may have difficulties accessing or adhering to daily Pre-Exposure Prophylaxis (PrEP) medication.
“With the Scottish Government’s target to increase access to preventative medication, this will help reach communities that face challenges in accessing HIV services, including unhoused people, people who inject drugs, those who are trans and non-binary, women, and those from minority ethnic communities.
“We hope that extending the reach of this antiviral medication to more communities will support Scotland’s target of zero new HIV transmission by 2030.”
Find out more here: https://scottishmedicines.org.uk/about-us/latest-update/february-2025-decisions-news-release/